306297-56-3

Upstream product

• 79-04-9 chloroacetyl chloride 
• 203186-20-3 (R)-2-[(S)-1-(4-Iodo-phenyl)-ethylamino]-propionic acid ethyl ester 
• 2627-86-3 (S)-1-phenyl-ethylamine 
• 2354-91-8 (S)-2,2,2-trifluoro-(α-methylbenzyl)acetamide 
• 203186-18-9 (S)-2,2,2-trifluoro-N-(1-(4-iodophenyl)ethyl)ethanamide 
• 56639-48-6 4-iodo-α(S)-methyl-benzylamine 

Downstream Products

• 306297-60-9 4-{4-[1-(S)-(4-iodophenyl)ethyl]-3(S)-methyl-1-piperazinyl}-1-(tert-butoxycarbonyl)piperidine 
• 726188-52-9 (S)-1-[(S)-1-(4-Iodo-phenyl)-ethyl]-2-methyl-4-piperidin-4-yl-piperazine 
• 306297-58-5 1-[1(S)-4-iodophenylethyl]-2(S)-methylpiperazine 

Relevant academic research and scientific papers

Piperazine derivatives useful as CCR5 antagonists

The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1is hydrogen or alkyl; R2is substituted phenyl, substituted heter

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4methyl-4-[3(S)-methyl-4-[1(S)-[4- (trifluoromethyl) phenyl]ethyl]-1-piperazinyl]piperidine N1-oxide (Sch-350634), an orally bioavailable, poten

Truncation of the original piperidino-2(S)-methyl piperazine lead structure 2, from a family of muscarinic antagonists, gave compound 8 which has improved selectivity for the HIV-1 co-receptor CCR5 over muscarinic receptors. Further optimization for pharm